The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:967-969 February 28, 2008 Number 9
NextNext

Zoledronate, Fractures, and Mortality after Hip Fracture

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Calis, K. A.
-Related Article
by Lyles, K. W.
-PubMed Citation
To the Editor: The increased use of composite end points in clinical studies makes it harder for clinicians to translate the findings into treatment decisions. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture Trial, reported by Lyles et al. (Nov. 1 issue)1 is no exception.

In this study, the primary end point was new clinical fractures, which included burdensome but relatively less severe fractures, such as vertebral fractures, and potentially life-threatening hip fractures. The absolute risk reduction for the primary end point was a significant 5.3%. However, the risk reduction for the clinically important . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.